香雪制药(300147) - 2025 Q3 - 季度财报

Financial Performance - Q3 2025 revenue was CNY 327,919,419.86, a decrease of 24.96% year-over-year[4] - Net loss attributable to shareholders was CNY -128,027,968.87, down 55.04% compared to the same period last year[4] - Total operating revenue decreased to ¥1,145,913,241.87 from ¥1,533,560,038.60, representing a decline of approximately 25.3% year-over-year[17] - Net profit for the period was a loss of ¥339,087,946.76, compared to a loss of ¥196,889,583.22 in the previous period, indicating a worsening of approximately 72.0%[18] - The company reported a total comprehensive loss of ¥339,447,903.88, compared to a loss of ¥196,954,831.78 in the previous period, indicating an increase in losses of approximately 72.2%[18] - Basic and diluted earnings per share were both reported at -¥0.55, compared to -¥0.33 in the previous period, reflecting a decline in performance[18] Cash Flow and Liquidity - Cash flow from operating activities increased by 175.41% year-to-date, totaling CNY 27,270,008.25[4] - Operating cash flow generated was ¥27,270,008.25, a significant improvement from a negative cash flow of ¥36,164,599.65 in the prior period[19] - Cash and cash equivalents at the end of the period totaled ¥119,423,134.37, compared to ¥65,733,446.88 at the end of the previous period, showing an increase of approximately 81.5%[20] - The company experienced a net cash outflow from investing activities of ¥13,391,083.96, compared to a net inflow of ¥27,951,254.29 in the prior period[19] - Total cash inflow from financing activities was ¥98,243,361.02, compared to ¥38,496,807.35 in the previous period, indicating an increase of approximately 155.5%[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 7,364,569,652.39, a decrease of 1.78% from the previous year[5] - The company's total liabilities increased to ¥6,265,814,683.02 from ¥6,059,565,986.39, indicating a rise in financial obligations[15] - The company's inventory decreased to ¥298,118,335.24 from ¥340,919,525.62, a decline of approximately 12.5%[14] - The total equity attributable to the parent company decreased to ¥692,637,257.30 from ¥1,054,899,213.92, a significant drop of about 34.3%[16] - The company reported a net loss in retained earnings, which worsened to -¥2,198,160,362.47 from -¥1,836,258,362.97[16] - The non-current liabilities decreased significantly to ¥217,539,784.45 from ¥677,549,244.88, indicating a reduction in long-term financial commitments[15] - The company’s short-term borrowings slightly decreased to ¥1,344,464,472.53 from ¥1,355,145,836.75, a reduction of about 0.8%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 34,981[10] - The largest shareholder, Guangzhou Kunlun Investment Co., Ltd., holds 22.59% of the shares, with 144,524,872 shares pledged[10] Government Support and Accounting Changes - The company received government subsidies totaling CNY 2,132,592.26 during the reporting period[6] - The new accounting standards will be implemented starting from 2025[22] Other Financial Metrics - The weighted average return on equity was -16.49%, a decrease of 11.77% year-over-year[4] - The company reported a significant increase in inventory impairment losses, up 1620.76% compared to the previous period[9] - Research and development expenses were ¥48,816,040.21, down from ¥53,060,653.17, reflecting a decrease of about 8.5% year-over-year[17] Audit Status - The third quarter financial report of the company has not been audited[21] Financial Restructuring - The company received a court decision extending its pre-restructuring period until January 11, 2026, indicating ongoing financial restructuring efforts[13]